Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma

• Sponsor: sohaila Essam (Other)
• Overall Status: Unknown status
• CT.gov ID: NCT04113278
• Collaborator: (none)
• Enrollment: 1
• Anticipated Duration (Months): 22

Study Details

Study Description

Brief Summary

The study population was selected from high grade glioma pateints attending the Department of Clinical Oncology, Assiut University hospital during the period from December 2018 to September 2020, we analyzed human high grade gliomas paraffin block for FLG2 expression

Condition or Disease	Intervention/Treatment	Phase
Brain Tumor Adult	Genetic: FGL2 immunohisyochemistry

Detailed Description

Glioblastoma is the most common malignant primary brain tumor in adults, and despite aggressive treatment, it is incurable Patient prognosis differs considerably within the different World Health Organization (WHO) grades, poorest prognosis for patients with the grade IV tumour- the glioblastoma multiform (GBM).

Fibrinogen-like protein 2 (FGL2),regulates both innate and adaptive immunity. FGL2 is a 439 amino acid secreted protein that is similar to the β- and γ-chains of fibrinogen.

Secreted FGL2 (sFGL2) is the key regulator in immunosuppression may play important role in malignant transformation of low to high by inhibiting the proliferation of T cell Study the role of fibrinogen-like protein2 on Immunosuppression and progression ，free survival and overall survival in high grade glioma

Study Design

• Study Type: Observational
• Anticipated Enrollment: 1 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma
• Anticipated Study Start Date: Nov 1, 2019
• Anticipated Primary Completion Date: Sep 1, 2020
• Anticipated Study Completion Date: Sep 1, 2021

Outcome Measures

Primary Outcome Measures

1. Rple of FGL2in high grade glioma as aprognostic factor [baseline]

   Correlation between FLG2 expression and progression free survival and overall survival

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 85 Years
• Sexes Eligible for Study: All

Inclusion Criteria:

• Pateints>18 years old

• Pathologically proven high grade glioma

• Total or subtotal resection of the tumor

• Patients received concurrent radiation therapy with temozolomide followed by adjuvant temozolamide for 6 months

Exclusion Criteria:

• Pregnancy

• Breast feeding

• Other comorbidity

• Previous malignancy or radiation therapy or chemotherapy

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• sohaila Essam

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

• Latha K, Yan J, Yang Y, Gressot LV, Kong LY, Manyam G, Ezhilarasan R, Wang Q, Sulman EP, Eric Davis R, Huang S, Fuller GN, Rao A, Heimberger AB, Li S, Rao G. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. J Natl Cancer Inst. 2019 Mar 1;111(3):292-300. doi: 10.1093/jnci/djy107.
• Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, Ott M, Xu J, Davis RE, Huo L, Rao G, Sun SC, Watowich SS, Heimberger AB, Li S. FGL2 promotes tumor progression in the CNS by suppressing CD103(+) dendritic cell differentiation. Nat Commun. 2019 Jan 25;10(1):448. doi: 10.1038/s41467-018-08271-x. Erratum in: Nat Commun. 2019 Feb 15;10(1):862.

• Responsible Party: sohaila Essam, Role of fibrinogen like protein 2 as aprognostic factor in high grade glioma, Assiut University
• ClinicalTrials.gov Identifier: NCT04113278
• Other Study ID Numbers: FGL2 in brain cancer
• First Posted: Oct 2, 2019
• Last Update Posted: Oct 2, 2019
• Last Verified: Oct 1, 2019

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of Oct 2, 2019